G. Tricot

G. Tricot, D. Reece, D. White, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

G. Tricot, D. Demarini, A. Roberts, 2009, Blood.

Diffuse fasciitis after bone marrow transplantation.

G. Tricot, R. Dom, J. Bulcke, 1987, The American journal of medicine.

detected by multiprobe interphase FISH High incidence of chromosome 13 deletion in multiple myeloma

B. Barlogie, G. Tricot, E. Tian, 2013 .

Anti-thymocyte globulin treatment for aplastic anemia.

G. Tricot, F. Zwaan, H. Haak, 2009, Scandinavian journal of haematology.

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma

G. Tricot, E. Tian, M. Zangari, 2021, Blood advances.

Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir.

B. Barlogie, N. Munshi, G. Tricot, 1997, Blood.

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

F. Zhan, G. Tricot, S. Janz, 2014, Immunologic research.

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

B. Barlogie, E. Anaissie, G. Tricot, 2003, Experimental hematology.

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

B. Barlogie, J. Shaughnessy, E. Anaissie, 2008, British journal of haematology.

Fatal Disseminated Adenoviral Infection Associated with Thrombotic Thrombocytopenic Purpura after Allogeneic Bone Marrow Transplantation

G. Tricot, A. Rapoport, C. Drachenberg, 2001, Leukemia & lymphoma.

Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

F. Zhan, L. Fink, G. Tricot, 2011, Clinical lymphoma, myeloma & leukemia.

Peripheral stem cell mobilization and engraftment in patients over age 60

B. Barlogie, S. Jagannath, G. Tricot, 1997, Bone Marrow Transplantation.

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone

G. Tricot, J. Kanda, J. Liesveld, 2013, Bone Marrow Transplantation.

High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.

G. Tricot, M. Pineda‐Roman, 2007, Contributions to Nephrology.

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

F. Zhan, B. Barlogie, J. Shaughnessy, 2007, Clinical Cancer Research.

Running title: Role of RAR 2 in multiple myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2013 .

RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.

F. Zhan, B. Barlogie, J. Shaughnessy, 2009, Blood.

RAR (cid:1) 2 expression is associated with disease progression and plays a crucial role in efﬁcacy of ATRA treatment in myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2009 .

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

G. Morgan, J. San Miguel, P. Sonneveld, 2003, The hematology journal : the official journal of the European Haematology Association.

FOXM1 is a therapeutic target for high-risk multiple myeloma

D. Hose, H. Goldschmidt, F. Zhan, 2016, Leukemia.

Analysis of human hematopoietic stem cell populations.

G. Tricot, Lesley J. Murray, A. Conti, 1994, Blood cells.

Case report Lymphomatoid granulomatosis following autologous stem cell transplantation

B. Barlogie, S. Jagannath, N. Munshi, 1999 .

Lymphomatoid granulomatosis following autologous stem cell transplantation

B. Barlogie, S. Jagannath, N. Munshi, 1999, Bone Marrow Transplantation.

Combined trisomy 1q and monosomy 7q due to translocation 1;7 in myelodysplastic syndromes.

G. Tricot, C. Mecucci, H. van den Berghe, 1985, Cancer genetics and cytogenetics.

Chromosome 13 Deletion/Hypodiploidy and Prognosis in Multiple Myeloma Patients

G. Tricot, A. Fassas, 2004, Leukemia & lymphoma.

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

B. Barlogie, S. Jagannath, S. Singhal, 1998, Bone Marrow Transplantation.

Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections.

K. Cornetta, G. Tricot, R. Hromas, 1995, The American journal of medicine.

Extreme potassium loss in a patient with severe graft versus host disease.

G. Tricot, F. Zwaan, H. Haak, 2009, Scandinavian journal of haematology.

The serial study of c-myc expression in bone marrow biopsy specimens during treatment for acute myelogenous leukaemia.

R. Larson, G. Tricot, H. Preisler, 1993, European journal of cancer.

The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes.

R. Larson, G. Tricot, G. Browman, 1994, Leukemia & lymphoma.

Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements

G. Tricot, R. Priore, K. Rai, 1986, British journal of haematology.

Transplants for multiple myeloma

B. Barlogie, S. Jagannath, G. Tricot, 1995 .

Autologous and allogeneic transplants for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Seminars in hematology.

Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation.

K. Cornetta, G. Tricot, R. Hromas, 1994, Bone marrow transplantation.

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma

F. Zhan, G. Tricot, Jianbo He, 2015, Oncotarget.

T‐cell chronic lymphocytic leukemia in a patient with invasive thymoma in remission with chemotherapy

G. Tricot, C. de Wolf‐Peeters, A. Broeckaert-van Orshoven, 1983, Cancer.

10. The use of unrelated donors for bone marrow transplantation

G. Tricot, 1997 .

Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience

B. Barlogie, S. Jagannath, D. Siegel, 2003, British journal of haematology.

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

F. Zhan, B. Barlogie, J. Shaughnessy, 2017, Leukemia.

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.

B. Barlogie, E. Anaissie, G. Tricot, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3q-, 3q+ anomaly in malignant proliferations in humans.

G. Tricot, C. Mecucci, H. van den Berghe, 1983, Cancer Genetics and Cytogenetics.

A chromosomal profile of polycythemia vera.

G. Tricot, C. Mecucci, H. van den Berghe, 1987, Cancer genetics and cytogenetics.

ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma

F. Zhan, G. Tricot, S. Janz, 2014, Leukemia.

Angiofollicular and plasmacytic polyadenopathy: a pseudotumourous syndrome with dysimmunity.

J. Diebold, G. Tricot, M. Tulliez, 1980, Journal of clinical pathology.

Interphase in situ hybridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypically normal relapse of acute lymphoblastic leukemia.

G. Tricot, N. Heerema, G. Argyropoulos, 1993, Leukemia.

Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia

N. Munshi, G. Tricot, 1997, Annals of Hematology.

Cytogenetic evaluation of bone marrow involvement in non-Hodgkin's lymphomas. A survey of 94 cases.

G. Tricot, M. Boogaerts, J. Michaux, 1984, Haematologica.

Inosine monophosphate dehydrogenase inhibitors. Probes for investigations of the functions of guanine nucleotide binding proteins in intact cells.

G. Tricot, R. Hoffman, M. Rizzo, 1990, Cellular signalling.

Infection – an underappreciated cause of bone pain in multiple myeloma

B. Barlogie, S. Jagannath, N. Munshi, 2003, British journal of haematology.

The blood coagulation mechanism in multiple myeloma.

B. Barlogie, L. Fink, G. Tricot, 2003, Seminars in thrombosis and hemostasis.

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.

F. Zhan, M. Dimopoulos, L. Fink, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

Bart Barlogie, Louis Fink, Joth Jacobson, 2004, British journal of haematology.

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.

B. Barlogie, L. Fink, E. Anaissie, 2002, Blood.

IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.

G. Tricot, Y. Yamaji, G. Weber, 1989, Leukemia research.

Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.

G. Tricot, K. Pennington, G. Weber, 1987, Cancer research.

Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

G. Tricot, M. Boogaerts, G. Cauwenbergh, 1987, Reviews of infectious diseases.

KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12.

N. Heerema, A. Antony, G. Tricot, 1988, Cancer genetics and cytogenetics.

Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.

G. Tricot, M. Zangari, K. Hanson, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Multiple myeloma

S. Singhal, C. Huff, G. Tricot, 2001, Bone Marrow Transplantation.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

5q- anomaly in a patient with disseminated teratoma.

G. Tricot, J. Fryns, P. Moerman, 1983, Cancer genetics and cytogenetics.

Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.

B. Barlogie, S. Jagannath, G. Tricot, 1998, Blood.

Progress in myeloma stem cells.

F. Zhan, G. Tricot, M. Zangari, 2011, American journal of blood research.

Interferon therapy in multiple myeloma: failure of human fibroblast interferon administration to the course of light chain disease.

G. Tricot, R. Verwilghen, A. Billiau, 1981, European journal of cancer & clinical oncology.

Tiazofurin: molecular and clinical action.

G Weber, G. Tricot, G. Weber, 1996, Anticancer research.

Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.

G. Tricot, G. Weber, 1996, Anticancer research.

Tiazofurin: biological effects and clinical uses.

G. Tricot, G. Weber, R. Hoffman, 1990, International journal of cell cloning.

Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.

C. Bloomfield, G. Tricot, S. Waxman, 2002, The oncologist.

Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.

G. Tricot, Y. Yamaji, G. Weber, 1988, Advances in enzyme regulation.

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

Bart Barlogie, Joth Jacobson, B. Barlogie, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.

G. Tricot, J. Eble, G. Weber, 1991, Cancer communications.

International uniform response criteria for multiple myeloma

B. Barlogie, G. Morgan, M. Dimopoulos, 2006, Leukemia.

Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.

B. Barlogie, S. Jagannath, N. Munshi, 1998, Blood.

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

F. Zhan, G. Tricot, S. Janz, 2014, Immunologic Research.

Hematopoietic stem cell transplantation.

B. Barlogie, S. Jagannath, G. Tricot, 1993, Hospital practice.

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Blood.

TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B-cell malignancies.

F. Zhan, J. Shaughnessy, G. Tricot, 2021, The Journal of clinical investigation.

Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma.

F. Zhan, P. Altevogt, M. Tomasson, 2019, Journal of the National Cancer Institute.

Graft-versus-myeloma effect: proof of principle.

B. Barlogie, S. Jagannath, N. Munshi, 1996, Blood.

18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib

F. Zhan, G. Tricot, L. Ponto, 2013, Blood Cancer Journal.

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1997, Blood.

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.

B. Barlogie, G. Tricot, R. Batchu, 2005, Cancer research.

Cytogenetics and Chromosomal Abnormalities in Multiple Myeloma-A Review

F. Zhan, G. Tricot, Kalyan Nadiminti, 2013 .

MDS‐type abnormalities within myeloma signature karyotype (MM‐MDS): only 13% 1‐year survival despite tandem transplants

B. Barlogie, J. Shaughnessy, G. Tricot, 2003, British journal of haematology.

Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma

B. Barlogie, J. Shaughnessy, N. Munshi, 2001, British journal of haematology.

Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression.

G. Tricot, R. Hoffman, A. Greist, 1990, JAMA.

Tumour lysis syndrome complicating high‐dose treatment in patients with multiple myeloma

B. Barlogie, N. Munshi, G. Tricot, 1999, British journal of haematology.

progression following tandem stem cell transplantation MGUS to relapsed myeloma and is related to prognosis and disease detected by fluorescence in situ hybridization: Incidence increases from Frequent gain of chromosome band 1q21 in plasma cell dyscrasias

Yongsheng Huang, J. Stewart, F. Zhan, 2013 .

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

Yongsheng Huang, J. Stewart, F. Zhan, 2006, Blood.

progression following tandem stem cell transplantation MGUS to relapsed myeloma and is related to prognosis and disease hybridization : Incidence increases from in situ detected by fluorescence Frequent gain of chromosome band 1 q 21 in plasma cell dyscrasias

Yongsheng Huang, J. Stewart, F. Zhan, 2006 .

Cytogenetics and molecular genetics in multiple myeloma.

G. Tricot, R. Feinman, J. Hardin, 1997, Hematology/oncology clinics of North America.

Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Third International Workshop on Chromosomes in Leukemia.

C. Bloomfield, J. Rowley, J. Whang‐Peng, 1983, Cancer research.

Thrombotic events in patients with cancer receiving antiangiogenesis agents.

F. Zhan, L. Fink, G. Tricot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

David R Williams, Bart Barlogie, Yongsheng Huang, 2006, Blood.

Complete response in myeloma: a Trojan horse?

B. Barlogie, G. Tricot, 2006 .

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

John Crowley, Erik Rasmussen, Bart Barlogie, 2006, The New England journal of medicine.

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

J. Crowley, B. Barlogie, B. Cheson, 1994 .

The 5q-anomaly.

G. Tricot, C. Mecucci, H. van den Berghe, 1985, Cancer genetics and cytogenetics.

Bone and paraproteinemias

F. Zhan, G. Tricot, M. Zangari, 2010, Current opinion in supportive and palliative care.

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.

B. Barlogie, J. Shaughnessy, G. Tricot, 2008, Blood.

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2

F. Zhan, G. Tricot, M. Zangari, 2010, Cancer biology & therapy.

Autotransplants in multiple myeloma: what have we learned?

B. Barlogie, B. Cheson, S. Jagannath, 1996, Blood.

Anomalies of the long arm of chromosome 11 in human myelo- and lymphoproliferative disorders. I. Acute nonlymphocytic leukemia.

G. Tricot, H. van den Berghe, J. Michaux, 1983, Cancer genetics and cytogenetics.

Chemotherapy plus radiotherapy in Clinical Stage IA to IIIB Hodgkin’s disease. Results of the H 77 trial (1977–1980)

G. Tricot, M. Weil, J. Andrieu, 1985 .

NY-ESO-1 immunotherapy for multiple myeloma

G. Tricot, F. van Rhee, S. Szmania, 2006, Leukemia & lymphoma.

Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.

F. Zhan, G. Tricot, Ye Yang, 2015, Cancer research.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

J Shaughnessy, B. Barlogie, J. Shaughnessy, 2001, Blood.

A reliable method with good cell preservation for the demonstration of peroxidase activity in human platelets and megakaryocytes

G. Tricot, R. Verwilghen, M. Heynen, 2004, Histochemistry.

Mechanisms of Thrombosis in Paraproteinemias: The Effects of Immunomodulatory Drugs

F. Zhan, L. Fink, G. Tricot, 2012, Seminars in Thrombosis & Hemostasis.

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.

Bart Barlogie, Louis Fink, Joth Jacobson, 2003, Clinical lymphoma.

Hemostatic dysfunction in paraproteinemias and amyloidosis.

L. Fink, G. Tricot, M. Zangari, 2007, Seminars in thrombosis and hemostasis.

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

F. Zhan, Gui-yuan Li, G. Tricot, 2010, Oncotarget.

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression

F. Zhan, J. Shaughnessy, G. Tricot, 2021, Cancers.

Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma

F. Zhan, G. Tricot, H. Bai, 2018, The Journal of clinical investigation.

ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning

B. Barlogie, N. Munshi, G. Tricot, 2002, Transfusion.

in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities,

B. Barlogie, J. Shaughnessy, S. Jagannath, 2013 .

patients treated since 1989 stem-cell mobilization: the Arkansas experience in more than 3000 autotransplantation for multiple myeloma linked to poor hematopoietic Cytogenetically defined myelodysplasia after melphalan-based

B. Barlogie, E. Anaissie, G. Tricot, 2013 .

High‐dose melphalan‐based autotransplants for multiple myeloma

B. Barlogie, E. Anaissie, G. Tricot, 2008, Cancer.

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

B. Barlogie, E. Anaissie, G. Tricot, 2008, Blood.

Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients

B. Barlogie, L. Fink, G. Tricot, 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma.

B. Barlogie, E. Anaissie, G. Tricot, 2006, Clinical lymphoma & myeloma.

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

John Crowley, Erik Rasmussen, Bart Barlogie, 2006, Blood.

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

F. Zhan, B. Barlogie, J. Shaughnessy, 2003, Blood.

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II

B. Barlogie, J. Shaughnessy, E. Anaissie, 2003, British journal of haematology.

Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants

B. Barlogie, N. Munshi, R. Desikan, 2002, British journal of haematology.

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2000, Blood.

Age is not a prognostic variable with autotransplants for multiple myeloma.

B. Barlogie, D. Siegel, S. Singhal, 1999, Blood.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1999, Blood.

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.

B. Barlogie, B. Cheson, S. Jagannath, 1994, Blood.

cells gammopathy of undetermined significance, and normal bone marrow plasma Global gene expression profiling of multiple myeloma, monoclonal

F. Zhan, B. Barlogie, J. Shaughnessy, 2011 .

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

John Crowley, Bart Barlogie, Johanna Hardin, 2002, Blood.

Molecular Profiling of Multiple Myeloma Running Head: Molecular Analysis of Myeloma Section: Neoplasia

F. Zhan, B. Barlogie, J. Shaughnessy, 2001 .

Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma.

G. Tricot, A. Fassas, 2001, Seminars in hematology.

Hematopoietic stem cell transplants for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1996, Leukemia & lymphoma.

Autophagy of mitochondria in rat bone marrow erythroid cells Relation to nuclear extrusion

G. Tricot, R. Verwilghen, M. Heynen, 2004, Cell and Tissue Research.

Cytogenetic patterns following bone marrow transplantation for chronic granulocytic leukemia.

N. Heerema, G. Tricot, J. Jansen, 1988, Cancer genetics and cytogenetics.

Bloodless tandem autologous transplant in Jehovah’s Witness patients

G. Tricot, S. Mott, Y. Jethava, 2018, Bone Marrow Transplantation.

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.

B. Barlogie, J. Mehta, R. Desikan, 2001, Blood.

Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients

G. Tricot, E. Waller, G. Long, 2015, Journal of clinical apheresis.

Prognosis and therapy in hairy cell leukemia.

G. Tricot, J. Hermans, R. Holdrinet, 1984, Seminars in oncology.

8;21 Translocation in acute myeloid leukemia an ultrastructural study

G. Tricot, A. van Orshoven, MD G. TRICOT, 1984, Cancer.

Pregnancy‐associated aplastic anemia ‐Report of 3 cases

G. Tricot, R. Hoffman, A. Golichowski, 1991, European journal of haematology.

Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Bone marrow transplantation.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

J. Witte, M. Lieber, G. Colditz, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Bone marrow histology in myelodysplastic syndromes

G. Tricot, C. Wolf‐Peeters, R. Verwilghen, 1984, British journal of haematology.

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?

F. Zhan, G. Tricot, S. Janz, 2015, Oncotarget.

Biology and therapy of multiple myeloma in 1996.

B. Barlogie, S. Jagannath, N. Munshi, 1997, Seminars in hematology.

A CASE OF HISTIOCYTOSIS X‐CENTRAL TYPE. HISTOLOGICAL, IMMUNOHISTOCHEMICAL AND ELECTRONMICROSCOPICAL ANALYSIS

G. Tricot, C. Wolf‐peeters, R. Vos, 1985, Pathology.

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus

F. Zhan, G. Tricot, J. Carew, 2015, Oncotarget.

Relapsing polychondritis: A paraneoplastic syndrome associated with myelodysplastic syndromes

G. Tricot, R. Hoffman, K. van Besien, 1992, American journal of hematology.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Response to bortezomib in refractory type I cryoglobulinemia

L. Fink, G. Tricot, M. Zangari, 2008, American journal of hematology.

Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

B. Barlogie, D. Siegel, R. Desikan, 2002, British journal of haematology.

Myeloma of the Central Nervous System: Strong Association with Unfavorable Chromosomal Abnormalities and Other High-risk Disease Features

G. Tricot, S. Ward, S. Harik, 2004, Leukemia & lymphoma.

Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant

B. Barlogie, E. Anaissie, G. Tricot, 2004, Bone Marrow Transplantation.

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.

B. Barlogie, S. Jagannath, D. Siegel, 1997, Leukemia & lymphoma.

Treatment of multiple myeloma.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004, Blood.

Hypercalcemia and diffuse osteolytic lesions in the acute phase of chronic myelogenous leukemia a possible relation between lymphoid transformation and hypercalcemia

G. Tricot, M. Boogaerts, A. Criel, 1983, Cancer.

Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284)

B. Barlogie, G. Morgan, M. Dimopoulos, 2006 .

A Complete Remission (CR) Is Not a Prerequisite for Prolonged Survival after Autotransplants for Multiple Myeloma.

B. Barlogie, G. Tricot, J. Sawyer, 2004 .

enhances natural killer cell-mediated lysis of myeloma Bortezomib down-regulates the cell surface expression of HLA-class I and

B. Barlogie, J. Shaughnessy, G. Tricot, 2013 .

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, British journal of haematology.

Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma

G. Tricot, M. Krasowski, U. Farooq, 2015, British journal of haematology.

Impact of a change in antibacterial prophylaxis on bacteremia and hospitalization rates following outpatient autologous peripheral blood stem cell transplantation for multiple myeloma

G. Tricot, M. Zangari, M. Boyer, 2014, Transplant infectious disease : an official journal of the Transplantation Society.

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

F. Zhan, J. Shaughnessy, G. Tricot, 2005, Blood.

Myelodysplastic syndromes complicating hematopoietic stem cell transplantation.

G. Tricot, A. Fassas, 2001, Cancer treatment and research.

Thrombosis in multiple myeloma

L. Fink, G. Tricot, M. Zangari, 2007, Expert review of anticancer therapy.

Encouraging preliminary results in 12 patients with high‐risk haematological malignancies by omitting graft‐versus‐host disease prophylaxis after allogeneic transplantation

G. Tricot, A. Rapoport, M. Cottler-Fox, 2000, British journal of haematology.

RARα2 expression confers myeloma stem cell features.

F. Zhan, G. Tricot, Wen Zhou, 2013, Blood.

NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma

F. Zhan, G. Tricot, Ye Yang, 2015, Clinical Cancer Research.

Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.

G. Tricot, S. Stass, R. Malone, 1999, Journal of biotechnology.

Stem Cell Factor

G. Demetri, G. Tricot, C. Begley, 2000 .

Bone marrow transplantation performed as first-time treatment in two cases of secondary acute myeloid leukemia.

G. Tricot, R. Verwilghen, P. Zachée, 1984, Leukemia research.

Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis

G. Tricot, C. Wolf‐Peeters, B. Hendrickx, 1985, British journal of haematology.

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

G. Tricot, R. Fenton, B. Mookerjee, 2002, Bone Marrow Transplantation.

induces spontaneous humoral and cellular immune responses NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and

F. Zhan, J. Shaughnessy, G. Tricot, 2013 .

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity

F. Zhan, G. Tricot, D. Bearss, 2014, BioMed research international.

Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma

B. Barlogie, S. Jagannath, G. Tricot, 1997, Bone Marrow Transplantation.

Trisomy-4 Identifies a Subset of Acute Nonlymphocytic Leukemias

G. Tricot, A. Delannoy, C. Mecucci, 1986 .

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization

G. Tricot, G. Calandra, M. Cottler-Fox, 2010, Bone Marrow Transplantation.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

G. Tricot, M. Territo, P. McCarthy, 2004 .

Killer Immunoglobulin-Like Receptor Ligand (KIR-Lig) Mismatched Natural Killer (NK) Cell Transfusions for Multiple Myeloma (MM).

B. Barlogie, J. Shaughnessy, G. Tricot, 2005 .

Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation

B. Barlogie, G. Tricot, M. Zangari, 2006, Bone Marrow Transplantation.

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma

F. Zhan, G. Tricot, S. Janz, 2014, Oncotarget.

Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT).

B. Barlogie, L. Fink, E. Anaissie, 2004 .

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma

F. Zhan, G. Tricot, B. Amendt, 2017, Oncotarget.

Adoptive B-cell transfer mouse model of human myeloma

F. Zhan, G. Tricot, S. Janz, 2015, Leukemia.

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma

F. Zhan, G. Tricot, S. Janz, 2015, Experimental Hematology & Oncology.

CDKN 1 A and FANCD 2 are potential oncotargets in Burkitt lymphoma and multiple myeloma

F. Zhan, G. Tricot, S. Janz, 2015 .

Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation

G. Tricot, A. Sherman, S. Simonton, 2004, Bone Marrow Transplantation.

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma

G. Tricot, M. Zangari, M. Boyer, 2019, Cell transplantation.

Predicting Long-term Survival in Multiple Myeloma Patients Following Autotransplants

G. Tricot, F. van Rhee, A. Fassas, 2003, Leukemia & lymphoma.

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

B. Barlogie, D. Siegel, S. Singhal, 1999 .

Thalidomide in the management of multiple myeloma.

B. Barlogie, E. Anaissie, G. Tricot, 2001, Seminars in oncology.

The role of cytogenetics in myeloma

G. Tricot, J. Sawyer, F. Zhan, 2006, Leukemia.

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma

F. Zhan, G. Tricot, R. Sompallae, 2018, BMC Cancer.

Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q

B. Barlogie, J. Shaughnessy, G. Tricot, 2005, Genes, chromosomes & cancer.

Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma

G. Tricot, J. Bolaños-Meade, I. Gojo, 2004, Bone Marrow Transplantation.

Spontaneous remission in myelodysplastic syndrome. A case report.

N. Heerema, G. Tricot, E. Broun, 1990, Cancer Genetics and Cytogenetics.

Marked Activity of Velcade Plus Thalidomide (V+T) in Advanced and Refractory Multiple Myeloma (MM).

B. Barlogie, G. Tricot, E. Rasmussen, 2004 .

The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia

G. Tricot, R. Verwilghen, R. Vlietinck, 1987, British journal of haematology.

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

B. Barlogie, L. Fink, R. Desikan, 2001, Blood.

Response to bortezomib and activation of osteoblasts in multiple myeloma.

D. Esseltine, G. Tricot, M. Zangari, 2006, Clinical lymphoma & myeloma.

C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

G. Tricot, U. Farooq, S. Mott, 2018, Cureus.

Clinical and biological features of multiple myeloma involving the gastrointestinal system.

B. Barlogie, G. Tricot, M. Zangari, 2006, Haematologica.

High-dose therapy and immunomodulatory drugs in multiple myeloma.

B. Barlogie, J. Shaughnessy, G. Tricot, 2002, Seminars in oncology.

Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma

G. Tricot, E. Tian, M. Zangari, 2021, American journal of hematology.

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

G. Tricot, M. Zangari, S. Kendrick, 2020 .

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

B. Barlogie, G. Morgan, G. Tricot, 2019, Blood.

Impact of bortezomib on bone health in myeloma: a review of current evidence.

F. Zhan, G. Tricot, M. Zangari, 2012, Cancer treatment reviews.

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

F. Zhan, S. Jagannath, A. Jakubowiak, 2011, European journal of haematology.

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

D. Esseltine, F. Zhan, G. Tricot, 2011, Haematologica.

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.

B. Barlogie, G. Tricot, R. Walker, 2006, Haematologica.

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

D. Esseltine, B. Barlogie, P. Sonneveld, 2005, British journal of haematology.

Hemopoietic stem cell transplants for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1994, Oncology.

Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism

L. Fink, G. Tricot, M. Zangari, 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.

R. Larson, G. Tricot, H. Preisler, 1991, Leukemia research.

What is the significance of molecular remission in multiple myeloma?

G. Tricot, 2007, Clinical advances in hematology & oncology : H&O.

Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a

F. Zhan, Xiaoke Ma, G. Tricot, 2020, Molecular Cancer Research.

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase

F. Zhan, G. Tricot, Jiliang Xia, 2017, Journal of Hematology & Oncology.

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

B. Barlogie, J. Shaughnessy, G. Tricot, 2006 .

Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM).

D. Campana, B. Barlogie, G. Tricot, 2005 .

Management of the myelodysplastic syndromes.

G. Tricot, F. Appelbaum, R. Hoffman, 1987, Seminars in oncology.

High-dose treatment (HDT) and autologous stem cell transplant (ASCT) in Waldenstrom’s macroglobulinemia (WM) patients (pts): A single center experience

B. Barlogie, G. Tricot, E. Rasmussen, 2005 .

Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients

B. Barlogie, R. Desikan, E. Anaissie, 2002, British journal of haematology.

Thalidomide in the management of multiple myeloma.

B. Barlogie, E. Anaissie, G. Tricot, 2001, Seminars in hematology.

Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.

B. Barlogie, G. Tricot, Steven Edward Kern, 2009, Journal of the National Cancer Institute.

Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM).

B. Barlogie, E. Anaissie, G. Tricot, 2006 .

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

G. Tricot, H. Nahi, M. Zangari, 2015, Clinical Cancer Research.

A Phase I Dose-Escalation Study of Antibody BI-505 inRelapsed / RefractoryMultipleMyeloma

G. Tricot, M. Zangari, M. Korsgren, 2015 .

Tamoxifen-based Treatment Induces Clinically Meaningful Responses in Multiple Myeloma Patients with Relapsing Disease after Autotransplantation

G. Tricot, A. Rapoport, M. Cottler-Fox, 2001, Leukemia & lymphoma.

Successful bone marrow transplantation for aplastic anemia using a HLA phenotypically identical parent.

G. Tricot, L. Sabre, F. Zwaan, 1981, Transplantation.

Involvement of guanine nucleotides in superoxide release by fluoride-treated neutrophils. Implications for a role of a guanine nucleotide regulatory protein.

G. Tricot, R. Hoffman, M. Rizzo, 1989, Journal of immunology.

Evaluation of bone marrow transplantation for haematological disorders.

G. Tricot, R. Verwilghen, E. Van Der Schueren, 1985, Acta clinica Belgica.

Successful mobilization of peripheral blood stem cells (PBSCs) with AMD3100 in patients failing to collect with hematopoietic growth factors (HGF) and/or chemotherapy.

G. Tricot, G. Calandra, A. Fassas, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in the myelodysplastic syndromes.

G. Tricot, G. Tricot, 1992, Leukemia research.

Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease

G. Tricot, C. Mecucci, H. Berghe, 1986, British journal of haematology.

The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations

G. Tricot, C. Wolf‐Peeters, R. Verwilghen, 1985, British journal of haematology.

c-myc and c-myb expression in acute myelogenous leukemia.

R. Larson, G. Tricot, H. Preisler, 1992, Leukemia research.

Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma - Early Results from Total Therapy III.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

MRI-Detectable Focal Lesions (FL) in Multiple Myeloma (MM) at Relapse Frequently Involve Novel Sites Not Involved at Diagnosis.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

B. Barlogie, E. Anaissie, G. Tricot, 2004 .

Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

Anti-IL6 Antibody (ab) Based Strategies Improve the Management of HIV Negative Castleman’s Disease.

B. Barlogie, N. Munshi, G. Tricot, 2004 .

L. Fink, G. Tricot, R. Marlar, 2007 .

Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma

G. Tricot, M. Tan, I. Gojo, 2006, Bone Marrow Transplantation.

Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.

G. Tricot, L. Akard, E. R. Broun, 1990, Bone marrow transplantation.

Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation.

K. Cornetta, G. Tricot, R. Hromas, 1996, Bone marrow transplantation.

EVOLUTION OF THE MYELODYSPLASTIC SYNDROMES

G. Tricot, C. Mecucci, H. van den Berghe, 1986, British journal of haematology.

Retroviral-mediated gene transfer of bone marrow cells during autologous bone marrow transplantation for acute leukemia.

K. Cornetta, G. Tricot, W. Anderson, 1992, Human gene therapy.

Thrombocytopenia as presenting symptom of preleukaemia in 3 patients.

G. Tricot, R. Verwilghen, A. Criel, 2009, Scandinavian journal of haematology.

[Immunoblastic lymphoma after bone marrow graft. Apropos of a case treated by OKT3 monoclonal antibodies for an acute graft versus host reaction].

G. Tricot, E. Gluckman, P. Faure, 1986, Annales de pathologie.

High-dose melphalan (MEL) based autotransplants (AT) for multiple myeloma (MM): The Arkansas experience since 1989 in more than 2,800 patients

B. Barlogie, E. Anaissie, G. Tricot, 2007 .

Melphalan 200mg/m2 (MEL 200) and MEL 140/DT-PACE Are Equally Effective in Multiple Myeloma (MM), While the Latter Is Less Toxic.

B. Barlogie, G. Tricot, M. Zangari, 2005 .

Third Autotransplant for the Management of 98 Patients among 1358 Who Had Received Prior Tandem Autotransplants: Benefit Apparent When 2nd to 3rd Transplant Interval Exceeds 3 Years.

B. Barlogie, E. Anaissie, G. Tricot, 2004 .

for Previously Untreated Multiple Myeloma Superiority of Tandem Autologous Transplantation Over Standard Therapy

B. Barlogie, B. Cheson, S. Jagannath, 2013 .

New insights into role of microenvironment in multiple myeloma

G. Tricot, 2000, The Lancet.

Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation

G. Tricot, R. Hromas, K. Sundblad, 1994, Antimicrobial Agents and Chemotherapy.

Extramedullary disease in myelodysplastic syndromes.

G. Tricot, A. Moriarty, M. A. da Silva, 1988, The American journal of medicine.

Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost,

G. Tricot, J. Kanda, J. Liesveld, 2011 .

Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy

G. Tricot, I. Gojo, A. Rapoport, 2001, Bone Marrow Transplantation.

Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice.

G. Tricot, 1992, Leukemia research.

11q23 involvement in a complex insertion (10; 11) in acute monocytic leukemia.

G. Tricot, C. Mecucci, H. van den Berghe, 1986, Leukemia research.

8/21 translocation in acute myeloid leukaemia.

G. Tricot, H. Berghe, H. van den Berghe, 2009, Scandinavian journal of haematology.

cells within chronic myeloid leukemia marrow Identification of BCR/ABL-negative primitive hematopoietic progenitor

G. Tricot, R. Hoffman, E. Srour, 2010 .

Bone Mineral Density Changes In Patients with Paraproteinemia After Treatment with Bortezomib

F. Zhan, G. Tricot, M. Zangari, 2010 .

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.

G. Tricot, M. Zangari, F. van Rhee, 2021, Haematologica.

Trisomy 4 identifies a subset of acute nonlymphocytic leukemias.

G. Tricot, A. Delannoy, C. Mecucci, 1986, Blood.

Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.

B. Barlogie, G. Tricot, V. Bolejack, 2005 .

Religious Struggle and Religious Comfort in Response to Illness: Health Outcomes among Stem Cell Transplant Patients

G. Tricot, A. Sherman, S. Simonton, 2005, Journal of Behavioral Medicine.

Sudan Black B positivity in acute lymphoblastic leukaemia

G. Tricot, R. Verwilghen, A. Hoof, 1982, British journal of haematology.

NEK 2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

F. Zhan, Z. Zeng, W. Xiong, 2013 .

Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.

G. Tricot, L. Suva, Ye Yang, 2014, Bone.

International uniform response criteria for multiple myeloma

B. Barlogie, G. Morgan, M. Dimopoulos, 2007, Leukemia.

Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.

B. Barlogie, G. Tricot, M. Zangari, 2002, The American journal of medicine.

Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium

N. Camp, J. Spinelli, S. Sanjosé, 2016, British journal of haematology.

Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1994, Journal of hematotherapy.

Total Therapy 3 (TT 3) for Newly Diagnosed Myeloma, Incorporating Velcade into Remission Induction with DT PACE: Early Results Regarding Efficacy, PBSC Mobilization and Toxicities.

B. Barlogie, G. Tricot, M. Zangari, 2004 .

Addition of Bortezomib (Velcade™) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM).

B. Barlogie, E. Anaissie, G. Tricot, 2004 .

Bortezomib Does Not Increase Thromboembolic Risk in Multiple Myeloma and May Offer a Protective Effect with Thalidomide/Lenalidomide-Based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens.

F. Zhan, L. Fink, G. Tricot, 2009 .

Chemotherapy-radiotherapy versus chemotherapy in Hodgkin's disease with bone marrow involvement. Retrospective analysis of 32 cases.

G. Tricot, B. Asselain, G. Flandrin, 1981, Acta haematologica.

Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Leukemia.

Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma.

F. Zhan, B. Barlogie, E. Anaissie, 2004 .

Multiple Myeloma: Role of Allogeneic Transplantation

G. Tricot, 2002 .

Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM).

B. Barlogie, E. Anaissie, G. Tricot, 2004 .

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma

G. Tricot, M. Zangari, F. van Rhee, 2021, Cancers.

Immunomodulatory drugs in multiple myeloma

G. Tricot, M. Zangari, F. Elice, 2005, Expert opinion on investigational drugs.

New insights into role of microenvironment in multiple myeloma

G. Tricot, 2002, International journal of hematology.

Composite Patient Reports: A Laboratory Informatics Perspective and Pilot Project for Personalized Medicine and Translational Research

G. Tricot, A. Gundlapalli, B. Jackson, 2009, Summit on translational bioinformatics.

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2005 .

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma

F. Zhan, J. Shaughnessy, G. Tricot, 2022, JAMA network open.

Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia

F. Zhan, B. Barlogie, J. Shaughnessy, 2018, Clinical Cancer Research.

Prognostic factors in multiple myeloma.

G. Tricot, 2005, Clinical advances in hematology & oncology : H&O.

Hemostatic dysfunction in paraproteinemias and amyloidosis.

L. Fink, G. Tricot, M. Zangari, 2007, Seminars in thrombosis and hemostasis.

Isolated peripheral thrombocytopenia as presenting symptom in preleukemia: a report of two cases with 11q+.

G. Tricot, H. van den Berghe, 1982, Cancer genetics and cytogenetics.

The AIS CELLector: a new technology for stem cell purification.

G. Tricot, J. Lebkowski, T. Okarma, 1992, Progress in clinical and biological research.

Cytogenetic findings in siblings with a myelodysplastic syndrome.

N. Heerema, G. Tricot, R. Hoffman, 1987, Cancer genetics and cytogenetics.

Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia.

Walker, C. Bloomfield, A. de la Chapelle, 1986, Blood.

Inhibition of DKK1 Activity Is Associated with Increased Osteoblast Numbers and Bone Formation, Reduced Osteoclast Activity and Inhibition of Tumor Growth in the SCID-rab Model for Primary Myeloma.

F. Zhan, B. Barlogie, J. Shaughnessy, 2005 .

Treatment of Multiple Myeloma

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

A subpopulation of lymph node B-CLL cells expresses the common acute lymphoblastic leukemia antigen.

V. Desmet, G. Tricot, J. J. van den Oord, 1984, Anticancer Research.

Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma

F. Zhan, J. Shaughnessy, G. Tricot, 2021, Blood.

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

A. Krishnan, S. Singhal, Rashmi Kumar, 2012, The Journal of the National Comprehensive Cancer Network.

[Pseudolymphoma and lymphoproliferative syndromes in Gougerot-Sjögren syndrome (author's transl)].

J. Diebold, G. Tricot, M. Tulliez, 1978, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[Visceral Kaposi sarcoma with angioimmunoblastic lymphadenopathy and latent sicca syndrome (author's transl)].

G. Tricot, M. Tulliez, S. Arkwright, 1980, Bulletin du cancer.

The histological characterization of ALIP in the myelodysplastic syndromes.

G. Tricot, R. Verwilghen, C. de Wolf‐Peeters, 1986, Pathology, research and practice.

The Prognostic Value of Abnormal Localization of Immature Precursors in the Myelodysplastic Syndromes

G. Tricot, C. Wolf‐peeters, M. T. Rizzo, 1992 .

Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma (MM)

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007 .

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312)

G. Morgan, P. Sonneveld, J. Miguel, 2004 .

Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes.

G. Tricot, S. Fruehauf, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

F. Zhan, L. Fink, G. Tricot, 2011, Clinical lymphoma, myeloma & leukemia.

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone

G. Tricot, J. Kanda, J. Liesveld, 2013, Bone Marrow Transplantation.

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma

N. Camp, J. Spinelli, S. de Sanjosé, 2018, Occupational and Environmental Medicine.

Cardiovascular Complications in Patients with AL Amyloidosis

F. Zhan, L. Fink, G. Tricot, 2011 .

Angiofollicular andplasmacytic polyadenopathy: a pseudotumourous syndrome withdysimmunity

G. Tricot, M. Tulliez, M. Reynès, 1980 .

prognosis to therapy define an aggressive multiple myeloma subtype with poor High serum-free light chain levels and their rapid reduction in response

J. Shaughnessy, E. Anaissie, G. Tricot, 2011 .

Collection of Peripheral Blood Stem Cells in 668 Patients with Multiple Myeloma Treated on Total Therapy II (UARK 98-026).

B. Barlogie, E. Anaissie, G. Tricot, 2004 .

Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing.

B. Barlogie, G. Tricot, E. Rasmussen, 2004 .